GALNT10 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7980209	1.00	1/20
SCHEMBL29370098	1.00	1/20
SCHEMBL26768213	0.79	1/20
SCHEMBL7987277	0.69	1/20
SCHEMBL2357304	0.68	1/20
SCHEMBL29466713	0.68	1/20
SCHEMBL29827270	0.68	1/20
SCHEMBL17949557	0.66	1/20
SCHEMBL7984298	0.66	1/20
SCHEMBL9748319	0.61	1/20
SCHEMBL21517158	0.61	1/20
SCHEMBL3874869	0.61	1/20
SCHEMBL15285080	0.61	1/20
SCHEMBL31414410	0.61	1/20
SCHEMBL7330918	0.60	1/20
SCHEMBL22431062	0.59	1/20
SCHEMBL1444851	0.58	1/20
SCHEMBL30451609	0.58	1/20
SCHEMBL5351976	0.58	1/20
SCHEMBL7227954	0.57	1/20

Clinical trials — most relevant to GALNT10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA	PHASE1/PHASE2	COMPLETED
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease	PHASE1/PHASE2	SUSPENDED
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
Clinical Trial Readiness for the Dystroglycanopathies	nan	RECRUITING
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Genetic Investigations in Children With Developmental and Epileptic Encephalopathies in Ho Chi Minh City, Vietnam	nan	UNKNOWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain	nan	UNKNOWN
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a GALNT10 binder may also engage these)

Protein	Name	Similarity
Q925R7	—	1.000	Q925R7 →
Q49A17	—	1.000	Q49A17 →
Q07537	—	0.999	Q07537 →
Q9JJ61	—	0.999	Q9JJ61 →
Q8N428	—	0.999	Q8N428 →
Q6P9S7	—	0.998	Q6P9S7 →
Q10473	—	0.998	Q10473 →
Q6WV17	—	0.998	Q6WV17 →
Q8MRC9	—	0.998	Q8MRC9 →
Q8BGT9	—	0.996	Q8BGT9 →
Q921L8	—	0.995	Q921L8 →
Q8MV48	—	0.995	Q8MV48 →
Q6P6V1	—	0.995	Q6P6V1 →
Q6DJR8	—	0.995	Q6DJR8 →
GALNT14	Polypeptide N-acetylgalactosaminyltransferase 14	0.995	landscape →
O61397	—	0.995	O61397 →
Q9R0C5	—	0.994	Q9R0C5 →
O08832	—	0.994	O08832 →
Q6WV20	—	0.993	Q6WV20 →
Q8IXK2	—	0.993	Q8IXK2 →
GALNT6	Polypeptide N-acetylgalactosaminyltransferase 6	0.993	landscape →
Q29121	—	0.993	Q29121 →
Q86SF2	—	0.993	Q86SF2 →
Q6PB93	—	0.993	Q6PB93 →
Q8CF93	—	0.992	Q8CF93 →
GALNT13	Polypeptide N-acetylgalactosaminyltransferase 13	0.992	landscape →
Q6UE39	—	0.992	Q6UE39 →
GALNT1	Polypeptide N-acetylgalactosaminyltransferase 1	0.992	landscape →
O08912	—	0.991	O08912 →
Q6WV19	—	0.991	Q6WV19 →